Management of immune-related cutaneous adverse events associated with immune checkpoint inhibitors in patients with cancer: an evidence summary.
OBJECTIVES: This study aims to systematically retrieve and synthesise the best available evidence on the management of immune-related cutaneous adverse events (ircAEs) associated with immune checkpoint inhibitors (ICIs) in patients with cancer, there. CONCLUSIONS: The evidence provides a structured basis for standardising ircAEs screening, nursing assessment, symptom management, referral and follow-up in patients receiving ICIs.
OBJECTIVES: This study aims to systematically retrieve and synthesise the best available evidence on the management of immune-related cutaneous adverse events (ircAEs) associated with immune checkpoint inhibitors (ICIs) in patients with cancer, there. CONCLUSIONS: The evidence provides a structured basis for standardising ircAEs screening, nursing assessment, symptom management, referral and follow-up in patients receiving ICIs.
What the study was
- Study design
- Systematic Review
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- BMJ open
Why it surfaced
Score 8/10: Systematic Review matching topic 'Novel therapeutics immunotherapy CAR-T'
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.